Commentary
2021-03-01
恆指季檢出爐 里康21760購/海撈28987購
大市上日(26日)急挫逾千點並以全日低位收市。預料大市今日能見反彈,看好可留意恆指牛證50427,收回價28750點,實際槓桿87.82倍,換股比率10000:1。相反看淡則可留意可留意新上市恆指熊證56631,收回價29719點,換股比率10000:1,為市場上最貼價之恆指熊證之一。
 
指數季檢結果出爐,恆指加入阿里健康(0241),龍湖集團(0960)及海底撈(6862),在沒有剔除其他成分股下成份股增至55隻,3月12日收市後正式生效。有分析指阿里健康及海底撈將分別帶動被動基金「追貨」14億元及9億元,投資者如看好可留意以下輪證部署。
 
里康購證21760,行使價31.18元,實際槓桿5.43倍,21年6月到期。
海撈購證28987,行使價75.88元,實際槓桿3.41倍,21年10月到期。
 
另外,踏入三月陸續有港股公佈業績,「信義系」旗下三家公司將於今日放榜。海通國際致力為投資者提供更多輪證選擇,有意進場部署可留意以下輪證。
 
信光購證29750,行使價21.93元,實際槓桿4.62倍,21年6月到期。
信義購證25987,行使價24元,實際槓桿4.2倍,21年6月到期。
獨家信能購證12237,行使價6.08元,實際槓桿2.49倍,21年12月到期。
The information on this material is provided and published by Haitong International Securities Company Limited (“HTI”), a corporation holding licences for Type 1 (dealing in securities) and Type 4 (advising in securities) regulated activities pursuant to the Securities and Futures Ordinance (Cap. 571). The contents of this material has not been reviewed or approved by the Securities and Futures Commission. Any and all information provided on this material is for reference only and does not constitute an offer, a solicitation of an offer or any advice or recommendation to buy or sell any financial products. The prices of structured products such as Warrants and/or CBBCs may fluctuate greatly and past performance is not indicative of future performance. The value of structured products may become zero on or before the expiry date and investors may sustain a total loss of investment. CBBCs have a mandatory call feature and are subject to early termination, upon which (i) investors in category N CBBCs will lose all their investments in CBBCs; and (ii) the residual value of category R CCBCs may be zero. Structured products issued by HTI or its affiliate are uncollateralised and investors are relying on the issuer’s credit worthiness in determining the issuer’s ability to meet its obligations under the structured products. If the Issuer is insolvent or defaults in payment, investors may not recover part or all of the amount due. An investor should read carefully the relevant listing documents (and any documents appendix thereto) and the relevant supplemental listing document to understand the full details of the warrant and/or CBBC (including risk factors), and due consideration have been given having considered the nature and risks involved in investing in these products, to decide whether the investment is suitable for an investor’s individual circumstances and, if necessary, an investor should consult their professional advisers. HTI is also the liquidity provider for the warrants and/or CBBCs (“Structured Products”) referred to in the material . HTI may be the only person quoting prices (or market making) for the Structured Products on the exchange. As such, the secondary market for the Structured Products may be limited. HTI (together with its subsidiaries and affiliates, “HTI Group”) provides the information in good faith and has used its best endeavours to ensure that the information provided is accurate and complete. HTI Group however does not represent or warrant the completeness or accuracy of the information and HTI Group. Haitong International Securities Company Limited may make a market in the securities and/ or the derivatives on these securities herein covered. Haitong International Securities Company Limited and/or its group company(ies) may have presently, or have had within the last 12 months, an investment banking relationship with the underlying entity of the securities herein covered. Haitong International Securities Company Limited is a member of Haitong International Securities Group which in turn belongs to group of companies of Haitong Securities Co., Ltd. HTISG and our affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this document. Haitong International Securities Company Limited and/or its group company(ies) and its affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this document.